Skip to content

Registry of First-line Treatments in Patients With Critical Limb Ischemia

National Registry Investigating the Effectiveness of Different First-line Treatment Strategies in Patients With Critical Limb Ischemia

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01877252
Acronym
CRITISCH
Enrollment
1200
Registered
2013-06-13
Start date
2013-01-31
Completion date
2014-09-30
Last updated
2014-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Limb Ischemia

Keywords

critical limb ischemia, endovascular treatment, open surgical repair, diabetic foot

Brief summary

The principal research question is which treatment modality between open surgical, endovascular and conservative therapy is the most effective in terms of limb salvage, survival and reinterventions in patients with critical limb ischemia

Detailed description

The target population consists of patients suffering from critical limb ischemia (CLI) lasting more than 2 weeks. CLI is defined as rest pain or tissue loss (Fontaine stages III-IV or Rutherford classes 4 to 6) and/or ankle-brachial index \< 0.40. Patient with acute limb-threatening ischemia, bone fractures in the relevant areas, nonatherosclerotic disease (e.g. arteriitis) and documented hypercoagulable diseases will be excluded from this study. There will be no experimental or control groups. The comparison groups will be: Group 1: Best endovascular treatment (angioplasty +/- stent) Group 2: Best surgical treatment \[bypass (vein or prosthetic)\] Group 3: Femoral artery patchplasty +/- profundoplasty (+/- endovascular treatment) Group 4: Best conservative treatment The proposed sample size amounts to 1200 patients. To be assessed for eligibility (n=1200) To be allocated to trial (n=1000) To be analysed (n=900) In CRITISCH registry, randomization or blinding is not feasible, because optimized standard care will be performed as established at each participating centre (best medical treatment). Data storage, validation, monitoring, update, backup and analysis will be performed centrally following established procedures. Web-based software will be used to develop a data model representing the data structure. The data validation will include standard data validation techniques such as the manual review of selected variables and the routine check of missing and outlying data points. Regional staff will be instructed and supervised by study nurse, who will perform the study monitoring. Assessment of relevant prognostic factors during the statistical analysis will prevent biased results due to the non-randomized design and the potential structural inequality.

Interventions

OTHERNo vascular intervention

Sponsors

Deutsches Institut für Gefäßmedizinische Gesundheitsforschung gGmbH (DIGG)
CollaboratorUNKNOWN
Deutsche Gesellschaft für Gefäßchirurgie und Gefäßmedizin
CollaboratorUNKNOWN
St. Franziskus Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Rest pain or tissue loss (Fontaine stages III-IV or Rutherford classes 4 to 6) and/or ankle-brachial index \< 0.40

Exclusion criteria

* Acute limb-threatening ischemia * Bone fractures in the relevant areas * Non-atherosclerotic disease (e.g. arteriitis) * Documented hypercoagulable diseases

Design outcomes

Primary

MeasureTime frameDescription
Amputation-free survivalat 2 yearsAbove-ankle amputation of the index limb or death (any cause), whichever occurred first

Secondary

MeasureTime frameDescription
Perioperative death30 days
Major adverse limb event (MALE)at 1 year, at 2 yearsabove ankle amputation of the index limb or major intervention (new bypass graft, jump/interposition graft revision, or thrombectomy/thrombolysis)
Major adverse cardiovascular event (MACCE)at 30 days, at 1 year, at 2 yearsmyocardial infarction, stroke or death (any cause)
Sustained clinical improvementat 1 year, at 2 yearsupward shift on the Rutherford or Fontaine classification to a level of intermittent claudication in amputation-free surviving patients without the need for repeated target lesion revascularization (TLR) (primary improvement) or after repeated TLR (secondary improvement)
Hemodynamic failureat 30 days, at 1 year, at 2 yearsfirst occurrence of any of the following events in a time-to-event fashion: (a) major amputation (transtibial or above) and/or (b) reintervention to maintain vascular patency in the index limb and/or (c) failure to increase ankle-brachial-index (ABI) by at least 0.15 postprocedure\] and/or (d) decrease in ABI by 0.15

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 11, 2026